JO
CBMG

John Overdeck’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

John Overdeck’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-23,999
Closed -$440K – 3930
2020
Q3 		$440K Buy
23,999
+8,148
+51% +$137K ﹤0.01% 2341
2020
Q2 		$237K Buy
+15,851
New +$226K ﹤0.01% 2527
2020
Q1 		– Sell
-20,974
Closed -$341K – 4079
2019
Q4 		$341K Buy
+20,974
New +$350K ﹤0.01% 3093

Other funds holding CBMG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

John Overdeck's CBMG Position: Q4 2020 in Review

John Overdeck sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 23,999 shares — an estimated $440K sold.

John Overdeck first reported a position in CBMG in Q4 2019 and held it in 3 quarters. The position peaked at $440K in Q3 2020. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

  • John Overdeck reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
  • John Overdeck sold 23,999 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $440K.
  • John Overdeck first reported a position in Cellular Biomedicine Group, Inc. in Q4 2019 and held it in 3 quarters.
  • John Overdeck's Cellular Biomedicine Group, Inc. position peaked at $440K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on Two Sigma Investments's 13F filing for Q4 2020, filed 16 Feb 2021.